Levi & Korsinsky notifies investors that it has commenced an investigation into Fulcrum Therapeutics, Inc. (NASDAQ: FULC) concerning potential violations of the federal securities laws.
Fulcrum lost approximately 50% of its value in a single session after disclosing on June 1, 2026, that the FDA had raised class-wide safety concerns about PRC2-targeting agents, leading the Company to discontinue the program of its lead candidate pociredir. In its 10-K filed February 24, 2026, Fulcrum disclosed insider equity positions totaling over 260,000 shares for certain executives. The stock traded above $20 in the months preceding the June 1, 2026 disclosure and declined to approximately $10 following the announcement. The 10-K also disclosed a long-term lease commitment of approximately $25.1 million for office and laboratory space, and referenced a CAMP4 Therapeutics agreement valued at up to $70 million in milestones plus royalties, with the upfront payment not separately quantified.
If you suffered a loss on your Fulcrum Therapeutics, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





